BD has announced allocation updates affecting products used in surgical preparation, vascular access, blood collection and medication delivery, creating additional purchasing considerations for hospitals heading into 2027.

According to the company’s November customer notices, six large-format ChloraPrep surgical applicators are subject to allocation levels ranging from 50% to 75%. BD attributed reduced output to planned equipment maintenance and validation work and expects short-term fulfillment delays through January 2027.

Separately, a supplier challenge has prompted allocation of all four products in BD’s PosiFlush prefilled heparin-lock flush syringe line. The company expects those restrictions to remain in place through the first quarter of 2027. PosiFlush saline flush syringes are unaffected, BD said in its Nov. 1 letter.

Three Vacutainer UltraTouch push-button blood-collection sets with preattached holders were placed on 75% allocation after orders exceeded forecasts. BD said it does not currently anticipate underlying supply constraints for those products.

BD also returned two hypodermic syringe codes to 100% allocation. That designation maintains established ordering limits rather than allowing unrestricted purchasing. The adjustments are part of ongoing monthly allocation management following federal action involving Chinese-manufactured syringes.

For healthcare supply chain teams, the notices underscore the need to review affected product codes, confirm distributor fulfillment expectations, and compare available inventory with procedural demand. Any proposed substitutions should involve the relevant clinical teams. For heparin-lock flush syringes, BD specifically advises evaluating alternatives against patient and vascular-access device needs, institutional policies and manufacturers’ instructions for use.